Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;39(9):675-678.
doi: 10.1038/s41371-025-01043-3. Epub 2025 Jul 14.

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension

Jaewon Oh  1 , Wonho Kim  2 , Gee-Hee Kim  3 , Hack-Lyoung Kim  4 , Sang-Don Park  5 , Kyung Wan Min  6 , Dongkeun Hyun  7 , Jun Hwa Hong  8 , Soo Lim  9 , Ji-Hwan Bae  10 , Jinho Shin  11 ; RESOLVE-INT Investigators
Affiliations

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension

Jaewon Oh et al. J Hum Hypertens. 2025 Sep.

Abstract

This pioneering study investigated the real-life effectiveness of single-pill combination (SPC) antihypertensive therapy in patients with uncontrolled blood pressure (BP) and cardiovascular risk factors. After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Jaewon Oh, Wonho Kim, Gee-Hee Kim, Hack-Lyoung, Sang-Don Park, Kyung Wan Min, Dongkeun Hyun, Jun Hwa Hong, and Soo Lim declare that they have no competing interests. Ji-Hwan Bae is a full-time employee of Daiichi Sankyo Korea Co., Ltd. Jinho Shin received honoraria from Daiichi Sankyo, Organon, Bristol Myers Squibb, Menarini, Sanofi, Hanmi, Boryung, Chong Kun Dang, and Daewoong, and grants from Sanofi and Hanmi. Ethical approval: This study was conducted according to ethical principles established by the Declaration of Helsinki. The Review Boards of participating institutions approved the protocol. All patients provided informed written consent.

Figures

Fig. 1
Fig. 1. Blood pressure changes from baseline in patients with apparent resistant hypertension and non-resistant hypertension over 24 weeks after starting OLM/AML/HCT.
AML amlodipine besylate, BP blood pressure, HCT hydrochlorothiazide, OLM olmesartan medoxomil, SPC single-pill combination. * P values were calculated using paired t tests: P < 0.0001 vs baseline.
See this image and copyright information in PMC

References

    1. Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ. 2024;385:e079108. - PubMed
    1. Park S, Shin J, Ihm SH, Kim KI, Kim HL, Kim HC, et al. Resistant hypertension: consensus document from the Korean society of hypertension. Clin Hypertens. 2023;29:30. - PMC - PubMed
    1. Brant LCC, Passaglia LG, Pinto-Filho MM, de Castilho FM, Ribeiro ALP, Nascimento BR. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022;24:55–66. - PubMed
    1. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481. - PubMed
    1. Oh J, Kim W, Kim GH, Kim HL, Park SD, Min KW, et al. Real-world effectiveness and safety of a single-pill combination of olmesartan/amlodipine/hydrochlorothiazide in Korean patients with hypertension and cardiovascular risk factors. Adv Ther. 2023;40:4817–35. - PMC - PubMed

MeSH terms

LinkOut - more resources